Hypothesis

15 Matching Annotations

Aug 2025
www.sciencedirect.com www.sciencedirect.com

Multimodal targeting of metastatic renal cell carcinoma via CD70-directed allogeneic CAR-NKT cells

1
1. scibot 30 Aug 2025
  
  in Public
  
  RRID:AB_10642829
  
  DOI: 10.1016/j.xcrm.2025.102321
  
  Resource: (BioLegend Cat# 350308, RRID:AB_10642829)
  
  Curator: @scibot
  
  SciCrunch record: RRID:AB_10642829
  
  What is this?
  
  RRID:AB_10642829
Visit annotations in context

Tags

RRID:AB_10642829

Annotators

scibot

URL

sciencedirect.com/science/article/pii/S2666379125003945
www.sciencedirect.com www.sciencedirect.com

Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells

1
1. scibot 13 Aug 2025
  
  in Public
  
  RRID:AB_10642829
  
  DOI: 10.1016/j.medj.2025.100804
  
  Resource: (BioLegend Cat# 350308, RRID:AB_10642829)
  
  Curator: @scibot
  
  SciCrunch record: RRID:AB_10642829
  
  What is this?
  
  RRID:AB_10642829
Visit annotations in context

Tags

RRID:AB_10642829

Annotators

scibot

URL

sciencedirect.com/science/article/pii/S2666634025002314
Jul 2025
www.sciencedirect.com www.sciencedirect.com

Protocol for assessing pharmacokinetics and pharmacodynamics of human CAR-NKT cells in humanized mouse models using bioluminescence imaging

1
1. scibot 22 Jul 2025
  
  in Public
  
  RRID:AB_10642829
  
  DOI: 10.1016/j.xpro.2025.103957
  
  Resource: (BioLegend Cat# 350308, RRID:AB_10642829)
  
  Curator: @scibot
  
  SciCrunch record: RRID:AB_10642829
  
  What is this?
  
  RRID:AB_10642829
Visit annotations in context

Tags

RRID:AB_10642829

Annotators

scibot

URL

sciencedirect.com/science/article/pii/S2666166725003636
May 2025
www.sciencedirect.com www.sciencedirect.com

Protocol to generate allorejection-resistant universal CAR-NKT cells and evaluate their efficacy, mechanism of action, safety, and immunogenicity

1
1. scibot 19 May 2025
  
  in Public
  
  RRID:AB_10642829
  
  DOI: 10.1016/j.xpro.2025.103810
  
  Resource: (BioLegend Cat# 350308, RRID:AB_10642829)
  
  Curator: @scibot
  
  SciCrunch record: RRID:AB_10642829
  
  What is this?
  
  RRID:AB_10642829
Visit annotations in context

Tags

RRID:AB_10642829

Annotators

scibot

URL

sciencedirect.com/science/article/pii/S2666166725002163
Apr 2025
pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov

Protocol to profile tumor and microenvironment from ovarian cancer patient samples and evaluate cell-based therapy using in vitro killing assays

1
1. scibot 18 Apr 2025
  
  in Public
  
  RRID:AB_10642829
  
  DOI: 10.1016/j.xpro.2025.103742
  
  Resource: (BioLegend Cat# 350308, RRID:AB_10642829)
  
  Curator: @scibot
  
  SciCrunch record: RRID:AB_10642829
  
  What is this?
  
  RRID:AB_10642829
Visit annotations in context

Tags

RRID:AB_10642829

Annotators

scibot

URL

pmc.ncbi.nlm.nih.gov/articles/PMC12002649/
May 2024
52.53.155.43 52.53.155.43

jitc-2023-December-11-12--inline-supplementary-material-1-html.html

2
1. scibot 17 May 2024
  
  in Public
  
  RRID:AB_10642829
  
  DOI: 10.1136/jitc-2023-007631
  
  Resource: (BioLegend Cat# 350308, RRID:AB_10642829)
  
  Curator: @scibot
  
  SciCrunch record: RRID:AB_10642829
  
  What is this?
  
  RRID:AB_10642829
2. scibot 02 May 2024
  
  in Public
  
  RRID:AB_10642829
  
  DOI: 10.1136/jitc-2023-007631
  
  Resource: (BioLegend Cat# 350308, RRID:AB_10642829)
  
  Curator: @scibot
  
  SciCrunch record: RRID:AB_10642829
  
  What is this?
  
  RRID:AB_10642829
Visit annotations in context

Tags

RRID:AB_10642829

Annotators

scibot

URL

52.53.155.43/17adc8dcdfe32fd9d6f43443a5653eac72124dab/jitc-2023-December-11-12--inline-supplementary-material-1-html.html
Oct 2023
www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov

Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design

2
1. scibot 11 Oct 2023
  
  in Public
  
  RRID:AB_10642829
  
  DOI: 10.1016/j.isci.2023.107952
  
  Resource: (BioLegend Cat# 350308, RRID:AB_10642829)
  
  Curator: @scibot
  
  SciCrunch record: RRID:AB_10642829
  
  What is this?
  
  RRID:AB_10642829
2. scibot 01 Oct 2023
  
  in Public
  
  RRID:AB_10642829
  
  DOI: 10.1016/j.isci.2023.107952
  
  Resource: (BioLegend Cat# 350308, RRID:AB_10642829)
  
  Curator: @scibot
  
  SciCrunch record: RRID:AB_10642829
  
  What is this?
  
  RRID:AB_10642829
Visit annotations in context

Tags

RRID:AB_10642829

Annotators

scibot

URL

ncbi.nlm.nih.gov/pmc/articles/PMC10558812/
Jun 2023
www.sciencedirect.com www.sciencedirect.com

DNA hypomethylation silences anti-tumor immune genes in early prostate cancer and CTCs

1
1. scibot 21 Jun 2023
  
  in Public
  
  RRID:AB_10642829
  
  DOI: 10.1016/j.cell.2023.05.028
  
  Resource: (BioLegend Cat# 350308, RRID:AB_10642829)
  
  Curator: @scibot
  
  SciCrunch record: RRID:AB_10642829
  
  What is this?
  
  RRID:AB_10642829
Visit annotations in context

Tags

RRID:AB_10642829

Annotators

scibot

URL

sciencedirect.com/science/article/pii/S0092867423005809
Mar 2023
www.sciencedirect.com www.sciencedirect.com

A bispecific T cell engager recruits both type 1 NKT and Vγ9Vδ2-T cells for the treatment of CD1d-expressing hematological malignancies

1
1. scibot 03 Mar 2023
  
  in Public
  
  RRID:AB_10642829
  
  DOI: 10.1016/j.xcrm.2023.100961
  
  Resource: (BioLegend Cat# 350308, RRID:AB_10642829)
  
  Curator: @scibot
  
  SciCrunch record: RRID:AB_10642829
  
  What is this?
  
  RRID:AB_10642829
Visit annotations in context

Tags

RRID:AB_10642829

Annotators

scibot

URL

sciencedirect.com/science/article/pii/S2666379123000538
Aug 2022
www.sciencedirect.com www.sciencedirect.com

Off-The-Shelf Third-Party HSC-Engineered iNKT Cells for Ameliorating GvHD While Preserving GvL Effect in the Treatment of Blood Cancers

1
1. scibot 17 Aug 2022
  
  in Public
  
  RRID:AB_10642829
  
  DOI: 10.1016/j.isci.2022.104859
  
  Resource: (BioLegend Cat# 350308, RRID:AB_10642829)
  
  Curator: @scibot
  
  SciCrunch record: RRID:AB_10642829
  
  What is this?
  
  RRID:AB_10642829
Visit annotations in context

Tags

RRID:AB_10642829

Annotators

scibot

URL

sciencedirect.com/science/article/pii/S2589004222011312
Nov 2021
www.sciencedirect.com www.sciencedirect.com

Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy

1
1. scibot 17 Nov 2021
  
  in Public
  
  RRID:AB_10642829
  
  DOI: 10.1016/j.xcrm.2021.100449
  
  Resource: (BioLegend Cat# 350308, RRID:AB_10642829)
  
  Curator: @scibot
  
  SciCrunch record: RRID:AB_10642829
  
  What is this?
  
  RRID:AB_10642829
Visit annotations in context

Tags

RRID:AB_10642829

Annotators

scibot

URL

sciencedirect.com/science/article/pii/S2666379121003177
Sep 2021
link.springer.com link.springer.com

Methods for Studying Mouse and Human Invariant Natural Killer T Cells

1
1. scibot 21 Sep 2021
  
  in Public
  
  RRID:AB_10642829
  
  DOI: 10.1007/978-1-0716-1775-5_4
  
  Resource: (BioLegend Cat# 350308, RRID:AB_10642829)
  
  Curator: @scibot
  
  SciCrunch record: RRID:AB_10642829
  
  What is this?
  
  RRID:AB_10642829
Visit annotations in context

Tags

RRID:AB_10642829

Annotators

scibot

URL

link.springer.com/protocol/10.1007/978-1-0716-1775-5_4
Jan 2020
www.sciencedirect.com www.sciencedirect.com

Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer

1
1. scibot 13 Jan 2020
  
  in Public
  
  RRID:AB_10642829
  
  DOI: 10.1016/j.stem.2019.08.004
  
  Resource: (BioLegend Cat# 350308, RRID:AB_10642829)
  
  Curator: @ethanbadger
  
  SciCrunch record: RRID:AB_10642829
  
  What is this?
  
  RRID:AB_10642829 RRIDCUR:Validated
Visit annotations in context

Tags

RRID:AB_10642829

RRIDCUR:Validated

Annotators

scibot

URL

sciencedirect.com/science/article/pii/S193459091930339X